Catalyst Crew Technologies Corp. (OTC: CCTC), a digital health and artificial intelligence technology company focused on emerging markets, announced today that it has assigned three Venezuelan patents to its wholly-owned operating subsidiary, Inversiones Long 33, C.A. The patents, previously held by CEO Dr. Kevin Rodan Levy, cover proprietary technologies known as CardioAI, PulmoAI, and NeuroAI, which are designed to support data-driven healthcare analytics, predictive modeling, and clinical decision-support applications.
This assignment aligns the Company’s intellectual property with its operating structure, positioning the subsidiary as the primary development and commercialization vehicle for its technology platform in the region. The Company believes that consolidating IP at the operating level enhances strategic flexibility, supports regulatory alignment, and may facilitate future partnerships, licensing opportunities, and regional expansion initiatives. In addition, the Company intends to pursue expanded intellectual property protection for its technologies in additional jurisdictions worldwide, as practical, in support of long-term platform development and potential international deployment.
Dr. Kevin Rodan Levy, Chief Executive Officer of Catalyst Crew Technologies Corp., stated: “Aligning our intellectual property within our operating structure is an important step as we continue building our platform. Establishing a clear foundation around our core technologies allows us to move forward with development, partnerships, and, where appropriate, broader intellectual property protection strategies across additional markets.”
The Company continues to advance the development of its digital health and artificial intelligence platform, with a focus on scalable healthcare solutions, including telehealth infrastructure, remote patient monitoring, and advanced healthcare analytics designed to improve access, efficiency, and care coordination. For more information, please visit https://catalystcrewai.com or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include, but are not limited to, statements regarding the Company’s business strategy, leadership initiatives, strategic transactions, operational execution, regulatory matters, and future operations. Forward-looking statements are based on current expectations and assumptions that involve risks and uncertainties. Actual results may differ materially from those expressed or implied due to various factors, including but not limited to the Company’s ability to successfully implement its business plan, secure financing, complete acquisitions, comply with regulatory requirements, and general market and economic conditions. The Company undertakes no obligation to update any forward-looking statements except as required by applicable law.
